A Multicentre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Initiation of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in India

Novo Nordisk A/S0 sites388 target enrollmentFebruary 24, 2023

ConditionsDiabetes Mellitus, Type 2

InterventionsOral semaglutide

DrugsOral semaglutide

Overview

Phase: Not Applicable
Intervention: Oral semaglutide
Conditions: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Enrollment: 388
Primary Endpoint: Change in Glycated haemoglobin A1c (HbA1c)
Status: Active, not recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. Participants will get oral semaglutide as prescribed to them by the study doctor. The study will last for about 8-11 months (34-44 weeks). Participants will be asked to complete a questionnaire about how they take oral semaglutide tablets. Participants will complete this questionnaire during the normal scheduled visit with the doctor and will be asked questions about their health and their diabetes treatment and lab tests as part of their normal doctor's appointment.

Registry

clinicaltrials.gov

Start Date

February 24, 2023

End Date

May 31, 2024

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•Diagnosed with type 2 diabetes (T2D).
•The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
•Male or female, age above or equal to 18 years at the time of signing informed consent.
•Available glycated haemoglobin A1c (HbA1c) value less than or equal to (\<=) 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with local clinical practice.
•Treatment naive to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than or equal to (\<=) 14 days.

Exclusion Criteria

•Previous participation in this study. Participation is defined as having given informed consent in this study.
•Any prior or current use of oral semaglutide.
•Hypersensitivity to oral semaglutide or to any of the excipients.
•Treatment with any investigational drug within 30 days prior to signing of informed consent.
•Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to signing of informed consent.
•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Arms & Interventions

Participants with type 2 diabetes

Adult participants with type 2 diabetes and naive to injectable glucose-lowering treatment.

Intervention: Oral semaglutide

Outcomes

Primary Outcomes

Change in Glycated haemoglobin A1c (HbA1c)

Time Frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)

Measured as percentage (%)-points.

Secondary Outcomes

Relative change in body weight(From baseline (week 0) to End of Study visit (V3) (week 34-44))
Absolute change in body weight(From baseline (week 0) to End of Study visit (V3) (week 34-44))
Glycated haemoglobin A1c (HbA1c) less than (<) 7%(At End of Study visit (V3) (week 34-44))
HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 5%(From baseline (week 0) to End of Study visit (V3) (week 34-44))
HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 3%(From baseline (week 0) to End of Study visit (V3) (week 34-44))